Evidence map›Paper›PMID 40069510›Full record

ArticleDigestive diseases and sciences2025

Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.

Lindsay Clarke, Ravi Teja Passam, Bryn Falahee, Pichamol Jirapinyo, Jessica R Allegretti, Colleen R Kelly

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lindsay ClarkeDivision of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ravi Teja PassamDepartment of Medicine, Wentworth Douglass Hospital, Dover, NH, USA.
Bryn FalaheeDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Pichamol JirapinyoDivision of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jessica R AllegrettiDivision of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Colleen R KellyDivision of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ckelly42@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlucagon-like peptide 1 receptor agonists (GLP-1 RA) have transformed obesity management, but their safety and efficacy in patients with inflammatory bowel disease (IBD) warrants further evaluation.

methodsThis retrospective cohort study included adults with obesity and a diagnosis of IBD who were treated with GLP-1 RA within a large healthcare network. Primary outcomes were ≥ 5% total weight loss (TWL) at 12-months post initiation, and IBD flares, comparing 12-months pre- and post-GLP-1 RA initiation. Secondary outcomes included ≥ 10% TWL, adverse events (AE), and discontinuation of GLP-1 RA. Secondary analysis assessed anti-TNF exposure and primary outcomes. Statistical analysis used paired t-test for continuous outcomes, and McNemar's χ

resultsOf 272 patients included, 175 completed at least 12 months of GLP-1 RA. Among these individuals, 61% achieved ≥ 5% TWL and 42% achieved ≥ 10% TWL. AEs occurred in 40%, and were primarily gastrointestinal (93%). GLP-1 RA were stopped in 24% of patients (48% for AE/tolerability and 18% for access/cost issues). There was no difference in the proportion of patients with IBD flares within 12 months pre vs. post GLP-1 RA (17% vs. 13%, P = 0.40). Anti-TNF exposure did not affect the likelihood of achieving ≥ 5% TWL in comparison with other IBD therapies (66% vs. 58%, P = 0.33).

conclusionsThis study supports the safety, tolerability, and effectiveness of GLP-1 RA for treatment of obesity in patients with IBD.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsInflammatory Bowel DiseasesObesityAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeWeight LossGlucagon-Like Peptide-1 Receptor AgonistsGLP-1IBDIncretinsObesity

Identifiers

PMID40069510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.